TIDMVENN

RNS Number : 1425I

Venn Life Sciences Holdings PLC

27 May 2014

   27 May 2014                                 Venn Life Sciences Holdings Plc

("Venn" or the "Company")

Director's Dealing

Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation (CRO) providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces that David Evans, a director, has today purchased 210,000 ordinary shares of 0.1 pence each in the Company at a price of 20.5 pence per share.

David Evans now holds 289,033 ordinary shares of 0.1 pence each, representing 1.03 per cent. of the Company's issued share capital.

 
 Enquiries: 
Venn Life Sciences Holdings Plc 
Tony Richardson, Chief Executive Officer   Tel: +353 154 99 341 
 
 
  Zeus Capital Limited (Nominated Adviser 
  and Broker) 
Ross Andrews/Andrew Jones (Corporate       Tel: 0161 831 1512 
 Finance) 
Dominic Wilson (Institutional Sales)       Tel: 020 7533 7727 
 
Walbrook PR Ltd                            Tel: 020 7933 8787 or venn@walbrookpr.com 
                                            Mob: 07980 541 893 
 Paul McManus 
Lianne Cawthorne                           Mob: 07584 391 303

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDSBXGDUXDDBGSR

Hvivo (LSE:HVO)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024 Plus de graphiques de la Bourse Hvivo
Hvivo (LSE:HVO)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024 Plus de graphiques de la Bourse Hvivo